392 related articles for article (PubMed ID: 32235443)
1. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
Cirmi S; El Abd A; Letinier L; Navarra M; Salvo F
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235443
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.
Zhao D; Long X; Wang J
BMC Pharmacol Toxicol; 2024 Feb; 25(1):20. PubMed ID: 38395895
[TBL] [Abstract][Full Text] [Related]
3. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
4. Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase
Cellier M; Bourneau-Martin D; Abbara C; Crosnier A; Lagarce L; Garnier AS; Briet M
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046701
[TBL] [Abstract][Full Text] [Related]
5. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.
Singh AP; Tousif S; Umbarkar P; Lal H
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549293
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
Anand K; Ensor J; Trachtenberg B; Bernicker EH
JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors.
Caocci G; Deidda M; Noto A; Greco M; Simula MP; Mulas O; Cocco D; Fattuoni C; Mercuro G; La Nasa G; Cadeddu Dessalvi C
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32326001
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
9. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.
Damrongwatanasuk R; Fradley MG
Curr Treat Options Cardiovasc Med; 2017 Apr; 19(4):24. PubMed ID: 28316033
[TBL] [Abstract][Full Text] [Related]
11. Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective.
Bauer S; Comer H; Ramsey B; Thomas K
J Adv Pract Oncol; 2021 Jul; 12(5):521-533. PubMed ID: 34430062
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.
Lai X; Wan Q; Jiao SF; Sun XC; Hu JF; Peng HW
Expert Opin Drug Saf; 2024 Mar; 23(3):287-296. PubMed ID: 37608525
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.
Pasvolsky O; Leader A; Iakobishvili Z; Wasserstrum Y; Kornowski R; Raanani P
Cardiooncology; 2015 Dec; 1(1):5. PubMed ID: 33530148
[TBL] [Abstract][Full Text] [Related]
14. Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS).
Gómez-Lumbreras A; Boyce RD; Villa-Zapata L; Tan MS; Hansten PD; Horn J; Malone DC
Ann Pharmacother; 2023 Oct; 57(10):1137-1146. PubMed ID: 36688283
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Cao Y; Lin Z; Zhou X; Guo Z; He J
Front Cardiovasc Med; 2021; 8():735466. PubMed ID: 34646873
[No Abstract] [Full Text] [Related]
16. Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Mulas O; Caocci G; Mola B; La Nasa G
Front Pharmacol; 2021; 12():674748. PubMed ID: 34630076
[No Abstract] [Full Text] [Related]
17. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Saydam G; Ali R; Demir AM; Eskazan AE; Guvenc B; Haznedaroglu IC; Ozcan MA; Salim O; Sonmez M; Tuglular AT; Turgut M; Unal A; Aver B; Bozkurt S; Ozdengulsun B; Ilhan O
Int J Hematol Oncol; 2022 Mar; 11(1):IJH38. PubMed ID: 35664044
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS.
Chen Y; Fan Q; Liu Y; Shi Y; Luo H
Psychiatry Res; 2023 Aug; 326():115300. PubMed ID: 37364503
[TBL] [Abstract][Full Text] [Related]
20. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
